Achieve Life Sciences reports Q1 net loss of $6.5M; cash $66.4M; ORCA-OL trial starts May 2024

ACHIEVE LIFE SCIENCES, INC.

2024-Q1 EPS reported -$0.26

Cash, cash equivalents, restricted cash $66.4M as of March 31, 2024, after $60M upfront financing.
Net loss for Q1 2024 was $6.5M; total operating expenses $6.0M.
Feb 2024 financing raised $60M upfront with potential $64.2M from milestone-driven warrants.
ORCA-OL long-term safety trial on track to initiate enrollment in May 2024; NDA submission expected H1 2025.
Phase 2 ORCA-V1 vaping cessation results published in JAMA Internal Medicine.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ACHIEVE LIFE SCIENCES, INC. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

ACHIEVE LIFE SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-056876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.